CN102357194B - Traditional Chinese medicine composition for preventing and treating lung injury due to radioactive radon and daughters thereof - Google Patents
Traditional Chinese medicine composition for preventing and treating lung injury due to radioactive radon and daughters thereof Download PDFInfo
- Publication number
- CN102357194B CN102357194B CN201110339057.0A CN201110339057A CN102357194B CN 102357194 B CN102357194 B CN 102357194B CN 201110339057 A CN201110339057 A CN 201110339057A CN 102357194 B CN102357194 B CN 102357194B
- Authority
- CN
- China
- Prior art keywords
- radon
- lung
- chinese medicine
- injury
- medicine composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Landscapes
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
The invention relates to a traditional Chinese medicine composition for preventing and treating lung injury due to radioactive radon and daughters thereof, that is a radon lung injury protective agent, and particularly is to develop a radon lung injury protective agent which can prevent and treat pneumonia, pulmonary fibrosis, and lung cancer caused by high radon exposure. The invention comprises traditional Chinese medicines which can tonify qi and nourish yin, clear heat and invigorate blood, strengthen body resistance and remove toxin, can reduce lung injury caused by high radon exposure, can be used for the prevention and treatment of pneumonia, pulmonary fibrosis, and lung cancer caused by radioactive radon and daughters thereof.
Description
Technical field
The present invention relates to prevent and treat radioactive radon and the Chinese medicine composition of daughter to injury of lung thereof, radon injury of lung protective agent, specifically develops a kind of radon injury of lung protective agent that can prevent and treat the pneumonia, pulmonary fibrosis and the pulmonary carcinoma that are caused by high radon exposure.
Background technology
The 15th century, in German Schneeberg ore deposit, miner easily suffers from a kind of pneumonopathy of high mortality, be referred to as " Schneeberg " pneumonopathy, the eighties in 19th century, this disease is confirmed to be pulmonary carcinoma, nineteen twenty-four has people to propose, and the pulmonary carcinoma that miner occurs may be relevant with the irradiation of radon.After this, massive epidemiology investigation shows: in high radon environment, the gamma-radiation of radon daughter can increase the risk factor of pulmonary carcinoma.The calculating such as Sacomano when radon and daughter thereof be subject to surpass 120 work level months (WLM) according to accumulation time sickness rate start to increase, surpass 1800WLM and significantly increase 20-30 doubly, mice is exposed in the gas and dust in these mines, can induces lung tumor.International cancer mechanism (IARC) has classified radon as I class carcinogen.
Radon (222Rn) is the decay constant of uranium, radium natural radionuclide, be present in surrounding air, by alpha-decay, generate multiple radon daughter, and its daughter has radioactivity equally, radon and daughter thereof are extensively present in atmospheric environment with gaseous state or solid-state form.In the whole natural background radiation dosage being subject to the mankind, approximately 54% irradiation from radon and daughter thereof.Environmental Radon and daughter thereof have been considered to cause after Nicotiana tabacum L. the second largest factor of pulmonary carcinoma to the harm of human body.In human lives's working environment, radon is mainly derived from subsurface rock (as solution cavity etc., Large Underground tunnel, mine etc.), soil and the indoor building material of special geology structure, and basement and underground space ventilation condition are poor, radon concentration is built far away higher than common ground.
Radon in atmospheric environment and daughter thereof enter in body by respiratory tract, its good fat-soluble being easy to absorbs through lung, the radon daughter major sedimentary of combined state is in pulmonary, unconjugated radon daughter major sedimentary is at nasopharynx part and trachea-bronchia, approximately 1/3 can shift and enter blood through lung, be distributed in whole body, therefore, lung and bronchial epithelial cell and hemocyte are the main target cells of radon and daughter thereof.
The generation of pulmonary carcinoma is both with the activation of oncogene and the sudden change of antioncogene or lack relevant, relevant with factors such as apoptosis of tumor cells inhibition again.Several genes, as survivin, methylthioadenodine phosphorylase (MTAP), human telomerase reverse transcriptase (hTERT) gene etc. have all participated in the generation evolution of pulmonary carcinoma.The mechanism of radon and daughter increase Lung Cancer Risk degree thereof may be inhaled into respiratory tract with radon and daughter thereof and be deposited on after pulmonary, causes radiation hazradial bundle, cause that the changes such as DNA chain interruption, base variation and albumen one DNA are cross-linked are relevant, but its precise mechanism it be unclear that.
Due to high mortality at short notice of pulmonary carcinoma with there is no at present radical cure means, therefore, the discovery of the biological indicator of pulmonary carcinoma early warning and screening become extremely important.At present, the diagnosis of pulmonary carcinoma is relied on to iconography and Protocols in Molecular Biology.For tumor marker, generally acknowledged index has carcinoembryonic antigen (CEA), CA125 (CA125), phosphoric acid Enolase (NSE), telomerase activation, p53 gene etc. at present.
CEA is a kind of acidoglycoprotein with human embryos antigenic specificity, that nineteen sixty-five Gold and Freeman extract in adenocarcinoma of colon tissue at first, first it be applied to clinical as the diagnosis marker of colon cancer, its sensitivity that adenocarcinoma is detected is adopted by clinical already.CEA not only has very high sensitivity in NSCLC diagnosis, in prognosis judgement, also has important value.
NSE is present in neuroendocrine cell and derives from the tumor cell of such cell.After breaking containing the cancerous cell of NSE, make NSE diffuse into blood and cause that in blood, NSE level raises.NSE is the most special the most responsive tumor markers of small cell lung cancer (SCLC).SCLC is a kind of tumor that comes from endocrine cell, and neuroendocrine cell and neurogenic tumour contain a large amount of NSE, and SCLC patient NSE positive rate is about 60%-80%, NSCLC patient NSE positive rate < 20%.The efficiency index that NSE or lung cancer chemotherapy effect observation are followed up a case by regular visits to, chemotherapy is produced to responder NSE can decline, and alleviation person NSE can reach normal level completely.
CEA, CYFRA 21-1, the NSE to 50 routine patients with lung cancer and 24 routine COPD patient's ria-determination serum and apoplexy due to phlegm such as Hillas G, the CYFRA 21-1 in serum distinguishes without obvious in two class patients; Patients with lung cancer apoplexy due to phlegm CYFRA 21-1 is higher 7 times than COPD patient, and has higher sensitivity and specificity.Hydrothorax CYFRA 21-1 particularly has higher diagnosis in NSCLC diagnosis in pulmonary carcinoma.It is followed successively by scale cancer, adenocarcinoma, large cell carcinoma, small cell lung cancer from high to low to the sensitivity of various pulmonary cancer diagnosis.
At present, still do not have prevention and treatment radon to cause the medicine of injury of lung (comprising pneumonia, pulmonary fibrosis and pulmonary carcinoma) both at home and abroad commercially available.
The object of the invention is to develop a kind of energy prevention and treatment and by high radon, exposed the radon injury of lung protective agent that causes pneumonia, pulmonary fibrosis and pulmonary carcinoma.
Summary of the invention
Content of the present invention is according to Chinese medicine principle with on the basis of proved recipe, to develop a kind of radon injury of lung protective agent.
Motherland's traditional medicine is thought, the heresy that ray is pyretic toxicity, and the most easily consumption is hindered human righteousness and cloudy blood.Weakened body resistance evil Sheng, the moon loses venation mistake and moistens, and causes the scorehed lung-lobe due to lung-heat, loses in respectful clearly functional activity of QI being not smooth; The bright Tianjin of heat wound, lung yin loss, healthy energy is more empty, controls joint mistake department, and hundred arteries and veins are obstructed towards meeting, become eventually body fluid deficiency the moon wound, the pathological change of venation block.Therefore, induced lung injury pathogenesis take that gas cloudy two loses, hot stasis of blood mutual resistance is as main, and treatment should QI invigorating righting, heat clearing and blood circulation promoting.
The Fuzheng Jiedu side that this research adopts, its Main Ingredients and Appearance comprises the Chinese medicines such as Cordyceps 5g, Radix Astragali 30g, Radix Salviae Miltiorrhizae 20g, Radix Ginseng Rubra (separately stewing) 10g, Radix Ophiopogonis 10g.Cordyceps has the effect of invigorating the lung and the kidney, hemostasis and phlegm, and can strengthen humoral immunization, suppress tumor growth, and the effect such as fibrosis; The Radix Astragali has the effect of invigorating QI to consolidate the body surface resistance, diuresis, expelling pus and toxin by strengthening QI, promoting tissue regeneration and ulcer healing, has the lung injury of alleviating and antitumor action; Radix Salviae Miltiorrhizae blood circulation promoting and blood stasis dispelling, fibrosis, have certain preventive and therapeutic effect to radiation fibrosis of lung, and kinds of tumor cells is had to cytotoxicity, can break up and apoptosis by inducing tumor cell, and can attack, shift by inhibition tumor cell; Radix Ginseng Rubra has the effect of stronger removing oxygen-derived free radicals lipotropism matter oxidation reaction, and the main component of Radix Ginseng Rubra extract is ginsenoside, has the ability of stronger removing oxygen-derived free radicals lipotropism matter oxidation reaction; Have YIN nourishing and the production of body fluid promoting, the lung moistening effect that clears away heart-fire Radix Ophiopogonis, cure mainly the diseases such as dryness of the lung dry cough, Tianjin wound is thirsty, Saponin C can improve immunity, improve myocardial function and tumor is had to certain inhibitory action Radix Ophiopogonis.
We have the effect of supplementing QI and nourishing YIN, heat clearing and blood circulation promoting, Fuzheng Jiedu, according to modern medical theory, can reduce by high radon and expose injury of lung, pulmonary fibrosis degree and the lung cancer incidence causing.
Preparation method: every dose of 250g adds water 500ml by traditional decocting medicine method slow fire boiling 30min, medicinal liquid is condensed into the decoction containing crude drug 1000g/L with thermostat water bath, vacuum packaging, 4 ℃ of Refrigerator stores.
According to the present invention, a kind of Chinese medicine composition of invention, radon injury of lung protective agent can prevent and treat by high radon and expose and cause pneumonia, pulmonary fibrosis and pulmonary carcinoma.
According to the present invention, for strengthening the curative effect etc. of radon injury of lung protective agent, the present invention has comprised Chinese medicine ingredients kind in radon injury of lung protective agent prescription, content is adjusted individually or increase the improved means such as adjuvant.
According to the present invention, in the radon injury of lung protective agent of invention, the preparation method of Chinese medicine can be different, as thick lifting manipulation, method for refining etc.
According to the present invention, the radon injury of lung protective agent of invention can be loaded into the not container such as grade, the variform tubulose of outer package, ampuliform of volume as required.
According to the present invention, the radon injury of lung protective agent of invention can be made into other dosage form by means known in the art, as oral liquid, teabag, pill, granule etc.
According to the present invention, radon injury of lung protective agent treatment of the present invention forms can apply separately the effective ingredient of this prescription or combine use with other medicines.
According to the present invention, treatment of the present invention forms, according to different situations, comprise pharmacokinetics, pharmacokinetics, the mode of administration of certain drug, character, degree and the treatment time limit etc. of receptor's age, body weight, hepatic and renal function state, disease, with appropriate dosed administration.
According to the present invention, enforcement of the present invention exposes and causes the prevention of induced lung injury (comprising radiation pneumonia, pulmonary fibrosis and pulmonary carcinoma etc.) and treatment to have important society, military affairs and economic benefit high radon.
The specific embodiment
Radon injury of lung protective agent using method and experimental result that the present invention develops are as follows:
1. animal grouping and radon expose:
18 of clean level male SD rats, body weight is (150 ± 20) g approximately.Be divided at random matched group, radon exposure group, radon injury of lung protective agent group, 6 every group.By radon expose group, radon injury of lung protective agent group rat is put into HD-3 type multifunctional ecological radon chamber, radon chamber ENVIRONMENT RADON CONTENT is 40000Bq/m3, it is 1890h that every rat exposes total time, i.e. 120 work level months (WLM), close rate is 0.056WLM/h.Radon injury of lung protective agent group rat gives 5ml (1000g/L) radon injury of lung protective agent gavage 1 time every day, and radon exposure group gives 5ml normal saline gavage 1 time every day; Control rats is fed in radon concentration is less than the room temperature environment of 50Bq/m3, and each organizes rat all freely movable, feed, regularly drinking-water.After experiment finishes (last has exposed), venous blood samples 5ml carries out pathological examination for blood serum tumor markers (CEA, neuronspecific enolase NSE) detection and the two lung preparations of collection immediately.
2. experimental result:
CEA, NSE concentration (μ g/L,
): matched group is respectively 12.352 ± 4.425,1.468 ± 0.147; Radon exposure group is respectively 396.620 ± 148.740,9.085 ± 0.896; Radon injury of lung protective agent group is respectively 70.885 ± 44.712,4.313 ± 1.366.Statistical analysis shows: radon exposure group CEA, NSE concentration are significantly higher than matched group, and difference has statistical significance (P < 0.05); Radon injury of lung protective agent group and the comparison of radon exposure group, radon injury of lung protective agent can significantly reduce rat blood serum CEA, NSE concentration, and difference has statistical significance (P < 0.05).
Two pneumonopathy check results of science: compare radon injury of lung protective agent group rat bronchioles and surrounding tissue inflammatory cell infiltration significantly reduces, emphysema degree significantly alleviates, incidence of thrombus significantly reduces in alveolar capillary with radon exposure group rat.
Above-mentioned experimental result demonstration, the radon injury of lung protective agent that the present invention develops can significantly reduce high radon and expose the extent of injury to injury of lung, can be used for the injury of lung that prevention and treatment radon and daughter thereof cause.
Claims (4)
1. can prevent and radiotherapy radon and the Chinese medicine composition of daughter to injury of lung thereof, it is characterized in that: crude drug is: Cordyceps 5g, Radix Astragali 30g, Radix Salviae Miltiorrhizae 20g, separately stew Radix Ginseng Rubra 10g, Radix Ophiopogonis 10g; Preparation method: every dose of 250g adds water 500ml, slow fire boiling 30 minutes, is condensed into the decoction containing crude drug 1000g/L by medicinal liquid with thermostat water bath, vacuum packaging, 4 ℃ of Refrigerator stores.
2. the Chinese medicine preparation that Chinese medicine composition claimed in claim 1 is made.
3. a preparation method for Chinese medicine composition as claimed in claim 1, is characterized in that: every dose of 250g adds water 500ml, and slow fire boiling 30 minutes, is condensed into the decoction containing crude drug 1000g/L by medicinal liquid with thermostat water bath, vacuum packaging, 4 ℃ of Refrigerator stores.
4. the purposes in the medicine that Chinese medicine composition claimed in claim 1 has prevention and the injury of lung that caused by radioactive radon and daughter thereof for the treatment of and pulmonary carcinoma in preparation.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201110339057.0A CN102357194B (en) | 2011-11-01 | 2011-11-01 | Traditional Chinese medicine composition for preventing and treating lung injury due to radioactive radon and daughters thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201110339057.0A CN102357194B (en) | 2011-11-01 | 2011-11-01 | Traditional Chinese medicine composition for preventing and treating lung injury due to radioactive radon and daughters thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN102357194A CN102357194A (en) | 2012-02-22 |
| CN102357194B true CN102357194B (en) | 2014-04-09 |
Family
ID=45582611
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201110339057.0A Expired - Fee Related CN102357194B (en) | 2011-11-01 | 2011-11-01 | Traditional Chinese medicine composition for preventing and treating lung injury due to radioactive radon and daughters thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102357194B (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111358888B (en) * | 2020-05-11 | 2022-04-29 | 青海珠峰冬虫夏草工程技术研究有限公司 | Traditional Chinese medicine composition for treating pulmonary fibrosis and preparation method and application thereof |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1437977A (en) * | 2003-01-13 | 2003-08-27 | 许新琳 | Medicine for treating lung cancer |
| CN101703726A (en) * | 2009-11-19 | 2010-05-12 | 何玉伟 | Medicament for treating lung cancer |
-
2011
- 2011-11-01 CN CN201110339057.0A patent/CN102357194B/en not_active Expired - Fee Related
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1437977A (en) * | 2003-01-13 | 2003-08-27 | 许新琳 | Medicine for treating lung cancer |
| CN101703726A (en) * | 2009-11-19 | 2010-05-12 | 何玉伟 | Medicament for treating lung cancer |
Non-Patent Citations (3)
| Title |
|---|
| 中药在放射性肺损伤防护中的作用;王景娜等;《现代肿瘤医学》;20081031;第16卷(第10期);第1800-1803页 * |
| 仲恒高等.氡及其子体吸入对大鼠肺与血细胞的氧化应激损伤.《苏州大学学报(医学版)》.2005,第25卷(第5期),第765-767页. * |
| 王景娜等.中药在放射性肺损伤防护中的作用.《现代肿瘤医学》.2008,第16卷(第10期),第1800-1803页. |
Also Published As
| Publication number | Publication date |
|---|---|
| CN102357194A (en) | 2012-02-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102641298A (en) | Effector cell combination for preventing and treating tumors and preparation method thereof | |
| CN101401866B (en) | Proprietary Chinese medicine medical ointment for treating radiation dermatitis | |
| CN102861284B (en) | Traditional Chinese medicine compound preparation for treating non-small cell lung cancer and preparation method thereof | |
| CN105169105A (en) | Chinese medicinal preparation having functions of preventing tumors, nourishing yin and stomach and enhancing immunity and preparation method thereof | |
| CN103405482A (en) | Application of salix leaf and wintersweet extract in preparation of medicines for treating inflammatory bowel diseases and alleviating digestive tract damage caused by chemotherapy drugs | |
| CN102357194B (en) | Traditional Chinese medicine composition for preventing and treating lung injury due to radioactive radon and daughters thereof | |
| CN103285106B (en) | Traditional Chinese medicinal composition for treating intestinal mucosa damage and preparation method and application thereof | |
| CN107875283A (en) | A kind of Chinese medicine compound prescription for treating lung cancer and preparation method thereof | |
| CN103417872B (en) | TCM composition for treatment of lung cancer and preparation method thereof | |
| CN103191191A (en) | Preparation method of traditional Chinese medicine composition for treating advanced non-small cell lung cancers | |
| CN102940871B (en) | Chinese medicament for treating chronic hepatitis | |
| CN102258676B (en) | Composition for preventing lung cancer, and preparation method and application thereof | |
| CN104306803A (en) | Traditional Chinese medicine composition for treating minimal residual leukemia | |
| CN108721532B (en) | For assisting in the treatment of the Chinese medicine composition of lung cancer | |
| CN105214067A (en) | A kind of medicine for the treatment of cancer patients diarrhoea | |
| CN105853618A (en) | Traditional Chinese medicine composition with broad-spectrum anti-cancer effect as well as preparation method and application thereof | |
| CN101584804A (en) | Traditional Chinese medicine for treating bronchogenic carcinoma | |
| CN100411663C (en) | Anticancer compound Chinese medicine powder and its preparing method | |
| CN104689088B (en) | A kind of Chinese medicine preparation and preparation method of prevention immunosenescence | |
| CN108498779A (en) | A kind of medicament and preparation method thereof for treating colon cancer | |
| CN105250911A (en) | Traditional Chinese medicine preparation for preventing and treating cancer and preparation method thereof | |
| CN107519365A (en) | Gram cancer dissipates and its instructions of taking | |
| CN102406873A (en) | Traditional Chinese medicine injection for treating gastric cancer | |
| CN106334140A (en) | Traditional Chinese medicine composition and preparation method thereof | |
| CN105687278A (en) | Pharmaceutical composition for treating middle and advanced stage lung cancer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20140409 Termination date: 20141101 |
|
| EXPY | Termination of patent right or utility model |